Optiscan was recently featured in The Age and Sydney Morning Herald regarding its strategic efforts to penetrate the U.S. healthcare market through high-profile industry events. The company is showcasing its ViewnVivo device which enables live, real-time cellular imaging during veterinary diagnostics and surgical procedures.

CEO Dr. Camile Farah emphasized the importance of these events, stating, “They give American surgeons, pathologists, and researchers the opportunity to get up close and personal with our innovative technology.” This non-invasive imaging solution is set to transform precision in veterinary care and has significant implications for human applications as well.

The ViewnVivo device, along with Optiscan's commitment to advancing diagnostic capabilities, aims to address the urgent need for improved veterinary services, particularly in cancer diagnosis, with over 12 million companion animals diagnosed annually.

As Optiscan expands its presence, it will continue to participate in key events, including the Mayo Clinic Beahrs Surgical Innovation Summit, reinforcing its reputation as a leader in high-resolution digital pathology solutions.

The Age - Access the full article here.

Sydney Morning Herald - Access the full article here.